Jean Crilly completed her Master of Science degree in Human Genetics from the University of Michigan in 2016. Under the guidance of Dr. JoAnn Sekiguchi, her thesis work characterized hypomorphic ARTEMIS mutant alleles associated with leaky severe combined immunodeficiency. Jean has nearly 7 years of experience working in the biotechnology industry, spanning manufacturing and drug discovery. She initially worked for Thermo Fisher Scientific, providing quality control for SNP genotyping microarrays. At her current role within 23andMe’s Therapeutics division, Jean and the team discover novel treatments for patients with unmet medical needs by leveraging the company’s genetic database. Jean is part of the Antibody and Protein Engineering group, in which she focuses on using phage display technology to select and identify antibody candidates for potential therapies and critical reagents. Her and the group characterize the therapeutic function of these antibodies and often further optimize them through engineering. Jean provides expertise to several programs in the 23andMe pipeline, which include therapies for oncology, respiratory, and cardiovascular diseases. She also provides support to programs in collaboration with GlaxoSmithKline.
Jean Crilly, M.S.
Senior Associate Scientist
Antibody and Protein Engineering
Human Genetics Ph.D. Program
University of Michigan